All of these drugs are tyrosine kinase inhibitors (TKIs), except for austocystin D. TKIs target the epidermal growth factor receptor (EGFR) and Erb-B2 Receptor Tyrosine Kinase 2 (ERRB2) pathways, which are known to play crucial roles in tumor progression and metastasis. Here, TYK2 is linked to neoplasm.